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doi:10.1016/j.jtcvs.2007.12.0161022 The Journal of Thoracic and CaObjective: The aim of this study was to determine whether or not resection of isolated
mediastinal lymph node renal cell carcinoma metastases confers a survival advantage,
as compared with patients with stage IV disease.
Patients and Methods: We retrospectively reviewed the charts of all patients with
renal cell carcinoma whose histologic specimens were evaluated at our institution
from January 1, 2000, through December 31, 2006. Using Kaplan–Meier esti-
mates, we compared the survival of patients who underwent resection of asyn-
chronous mediastinal lymph node metastases with that of patients with stage IV
disease.
Results: During the 7-year study period, of the 386 patients with renal cell carcinoma
who were evaluated at our institution, 9 underwent resection of asynchronous medi-
astinal lymph node metastases. After primary tumor resection and before diagnosis of
asynchronous mediastinal lymph node metastases, all patients completed chemother-
apy, cytokine therapy, or tumor vaccination; 3 underwent radiotherapy. The median
age at resection of mediastinal lymph nodes was 57.7 years (range, 39.7–81.2). The
median time from primary tumor resection to mediastinal lymph node resection
was 2.8 years (range, 0.5–23.3). In all, 4 patients underwent resection of metastases
via thoracotomy and 5, via thoracoscopy. The median number of mediastinal lymph
nodes pathologically evaluated was 7 (range, 2–28); the median number of positive
mediastinal lymph nodes per patient was 1.5 (range, 1–3). We found no surgical
complications. The median survival after resection of metastases (3.2 years) was
significantly longer (P 5 .021) than for other patients with stage IV disease at our
institution (1.1 years).
Conclusions: Resection of renal cell carcinoma mediastinal lymph node metastases is
safe, appears to extend survival, and should be considered an important component of
treating patients with renal cell carcinoma who have asynchronous mediastinal lymph
node metastases.
I
n 2007, about 51,190 persons in the United States will be diagnosed with renal
cell carcinoma (RCC) and 12,890 will die of it. Among incident cases, 45%
present as localized disease (American Joint Committee on Cancer1 stage I or
II), 25% present as locally advanced disease (stage III), and 30% present with meta-
static disease (stage IV).rdiovascular Surgery c May 2008
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TSAbbreviations and Acronyms
IL-2 5 interleukin 2
MLN 5 mediastinal lymph node
RCC 5 renal cell carcinoma
Patients with asynchronous RCC metastases have a more
favorable prognosis (median survival, 21 months)2 than
those with synchronous metastases (median survival, 10
months).3 Resection of synchronous metastases does not
impart a survival advantage.4 However, resection of isolated
abdominal and pulmonary parenchymal asynchronous me-
tastases results in a more favorable prognosis.4-7
In the treatment of patients with RCC with recurrent or ad-
vanced disease, the systemic medical therapies used are wide
and of limited efficacy. When we began seeing patients with
isolated mediasinal lymph node (MLN) metastases, we began
offering surgical resection as therapy because of the isolated
nature of their disease recurrence and the efficacy of current
medical therapies available. We could find no published re-
ports on the efficacy or possible survival advantage of resect-
ing isolated asynchronous MLN metastases in patients with
RCC. Traditionally, such patients have been treated with ei-
ther palliative or experimental chemotherapy.
The aim of this study was to determine whether patients
with RCC who undergo resection of isolated asynchronous
MLN metastases have a survival advantage as compared
with other patients having stage IV disease.
Methods
Data Collection
The University of Minnesota Institutional Review Board approved
this study and waived the need for informed consent. Using a databaseThe Journal of Thorprospectively maintained by the Department of Laboratory Medicine
and Pathology (J.J.), we retrospectively reviewed the charts of all
patients with RCC whose histologic specimens were evaluated at
our institution from January 1, 2000, through December 31, 2006.
By cross-referencing this dataset with the Section of Thoracic and
Foregut Surgery database (M.A.M., R.S.A.), we identified patients
with RCC who underwent resection of isolated asynchronous MLN
metastases at our institution (study cohort). We collected data on pa-
tient characteristics, comorbidities, perioperative details, neoadjuvant
and adjuvant therapy, tumor characteristics, and survivals.
To establish a control group for comparison with our study co-
hort, we used the University of Minnesota Cancer Center Registry
to collect data (eg, patient characteristics, tumor stage, survival)
on all patients with RCC treated at our institution.
Statistical Analysis
For statistical analyses, we used JMP for Windows, version 4.0.4
(SAS Institute, Inc, Cary, NC). Data are reported as mean6 standard
deviation unless otherwise noted. For between-group comparisons
of ordinal and nominal variables, we used a c2 test (a5.05); for con-
tinuous variables, we used a t test (a 5.05). For survival analyses,
two survival times were used. The first was the overall survival
time, from the time of diagnosis, defined as the time from diagnosis
to death or last available follow-up (for those patients with both
resectable and unresectable disease). The second survival time em-
ployed was the postresection survival time, from the time of resec-
tion, defined as the time from surgical resection to death or last
available follow-up (as recorded in the University of Minnesota
Cancer Center Registry at the time of initial manuscript submission).
For survival analyses, we used the Kaplan–Meier method. To com-
pare survival functions, we used a log–rank test (a 5 .05).
Results
Patient Characteristics
Over the 7-year study period, the Department of Laboratory
Medicine and Pathology evaluated 386 cases of RCC. OfTABLE 1. Patient and tumor characteristics (study cohort)
Patient Sex
Initial
stage*
Age at
metastasectomy
(y)
Time to MLN
metastasectomy
(y)
Time from
initial diagnosis
to last follow-up
(y)
Time from MLN
metastasectomy
to last follow-up
(y)
Surgical
approach
MLN size
(cm)
Motzer
scorey
Fuhrman
gradez
Angiolymphatic
invasion
1 M III 61 7.3 10.1 2.8 V 3.7 0 2 Yes
2 M III 81 23.3 23.5 0.2 T 4.2 0 2 Yes
3 M I 69 5.4 8.2 2.7 V 0.8 1 3 Yes
4 M I 59 0.7 3.9 3.2 T 2.8 0 2 Yes
5 F III 52 4.5 5.7 1.2 T 3 0 2 Yes
6 F III 40 0.5 1.1 0.6 T 2.5 0 3 Yes
7 M IV 50 2.8 3.9 1.1 V 7.6 0 3 Yes
8 M III 58 1 2.8 1.8 V 3.9 0 3 Yes
9 M III 54 0.7 1.8 1.2 V 5 0 3 Yes
V, Video-assisted thoracoscopic surgery; T, thoracotomy; M, male; F, female; MLN, mediastinal lymph node. *Stage based on American Joint Committee on
Cancer criteria.1 yMotzer score is the sum of the number of the following risk factors: hemoglobin# 13 g/dL (male) or# 11.5 g/dL (female), a corrected calcium
. 10 mg/dL, and a Karnofsky performance status, 80%.3 zFuhrman grade of 1 through 4, based on increasing nuclear size, cellular irregularity and nucleolar
prominence.8acic and Cardiovascular Surgery c Volume 135, Number 5 1023
General Thoracic Surgery Whitson et al
G
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Patient
First-line
therapy
Second-line
therapy
Third-line
therapy
Fourth-line
therapy
Fifth-line
therapy Alive
1 Nephrectomy Metastasectomy Sunitinib Yes
2 Nephrectomy Metastasectomy None Yes
3 Nephrectomy Metastasectomy None Yes
4* Nephrectomy HD IL-2 Metastasectomy LMI vaccine 852-A m-toll
agonist
Suramin
and
5-FU
Cetuximab No
5* Nephrectomy LMI vaccine Sunitinib Metastasectomy Sorafenib Yes
6 Nephrectomy LMI vaccine Metastasectomy HD IL2 Yes
7* Nephrectomy LMI vaccine Metastasectomy Sorafenib Yes
8 Nephrectomy HD IL-2 Sorafenib Metastasectomy Sunitinib Yes
9 Nephrectomy Metastasectomy Bevacizumab Yes
HD IL-2, High-dose interleukin 2; 5-FU, 5-fluorouracil; LMI, large multivalent immunogen; *Denotes radiation therapy.those 386 patients, 9 underwent resection of isolated asyn-
chronous MLN metastases (Table 1). All 9 patients had
undergone radical nephrectomy before MLN metastases
developed (Table 2); at that time, 6 had stage III disease.
The 1 patient with stage IV disease had an isolated humerus
metastasis that was treated with (and responded to) radiation
therapy. The median age at resection of MLN metastases was
57.7 years (range, 39.7–81.2), and the median interval from
primary tumor resection to metastasectomy was 2.8 years
(range, 0.5–23.3). New MLN metastases were identified
during routine surveillance, as part of the evaluation for other
procedures, or incidentally. Selected images (Figure 1) from
a fusion positron emission tomography/computed tomogra-
phy scan show increased metabolic activity within the medi-
astinum of 1 patient with MLN metastases.
Comorbidities
In general, the study cohort had minimal comorbidities.
There were the following conditions: hypertension (n 5 4),
gastroesophageal reflux disease (n 5 3), coronary artery
disease (n 5 2), type 2 diabetes mellitus (n 5 2), chronic1024 The Journal of Thoracic and Cardiovascular Surgery c Mobstructive pulmonary disease (n 5 1), tobacco use (n 5 2),
asthma (n 5 1), and chronic renal insufficiency (creatinine
.1.5 mg/dL) (n 5 0).
Perioperative Details
Of the 9 patients who underwent resection of MLN metasta-
ses, 5 underwent thoracoscopy and 4, thoracotomy. Blood
loss was minimal (range, 25–250 mL). The median operative
time was 210 minutes (range, 120–270 minutes). The median
number of MLNs pathologically evaluated was 7 (range
2–28). Of those MLNs, a median of 1.5 (range, 1–3) were pos-
itive for metastatic RCC, per our final pathologic examina-
tion. The median largest dimension of the histologically
positive MLN was 3.7 cm (range, 0.8–7.6).
The mean postoperative hospital length of stay was 4.16
3.3 days. Duration of chest tube placement was 2.9 6 2.1
days. There were no perioperative deaths. The only compli-
cation was related to chemotherapy: upper gastrointestinal
bleeding (diffuse gastritis on esophagogastroduodenoscopy)
in 1 patient resulted in acute blood loss anemia and the needFigure 1. Fusion positron emission tomography/computed tomography scan of an isolated RCC metastasis to station
4R (per American Thoracic Society) MLN (circled): coronal (A), axial (B), and sagittal (C) views. RCC, Renal cell
carcinoma; MLN, mediastinal lymph node.ay 2008
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TSfor blood transfusion. The mean survival time after resection
of MLN metastases was 3.9 years. The median time after
resection was more than 3.2 years (range, 2.8–.3.2 years);
of our 9 study cohort patients, at the end of the 7-year study
period, 1 had died, 1 had been lost to follow-up, and 7 were
alive and well (Table 2).
Figure 2. Hematoxylin and eosin histologic slide of a primary RCC
in the kidney, clear variant with a Fuhrman nuclear grade of 1 (A),
a normal MLN without metastasis (B), and an MLN with isolated
asynchronous RCC metastasis, clear cell variant, with a Fuhrman
nuclear grade of 2 (C). RCC, Renal cell carcinoma; MLN, mediasti-
nal lymph node.The Journal of ThoraNeoadjuvant and Adjuvant Therapies
Our 9 study cohort patients completed a variety of neoadju-
vant and adjuvant treatment regimens (Table 2): 4 received
a large multivalent immunogen vaccine; 3, high-dose inter-
leukin 2 (IL-2); 3, radiation therapy; 3, sunitinib (Sutent;
Pfizer Oncology, New York, NY); 3, sorafenib (Nexavar;
Onyx Pharmaceuticals, Inc, Emeryville, Calif); 1, cetuximab
(Erbitux; ImClone Systems Inc, New York, NY); 1, bevacizu-
mab (Avastin; Genentech, Inc, South San Francisco, Calif);
and 1, 852A (an experimental m-toll agonist).
Tumor Characteristics
Per our final histologic evaluation of the MLN specimens, no
obvious features distinguished the asynchronous metastases
from a typical RCC pattern (Figure 2). The median Fuhrman
grade8 was 3 (range 2–3) (Table 1). Minimal necrosis was
seen in the MLNs; however, we noted uniform angiolym-
phatic invasion.
Survival
From the University of Minnesota Cancer Center Registry,
we were able to gather complete data on 155 patients with
RCC who were diagnosed, treated, and followed up at our in-
stitution. The overall survival time of the patients with stage
I, II, and III disease at our institution did not significantly dif-
fer, so to increase the power of our subsequent analyses, they
were grouped together. Patients were thus stratified into 3 cat-
egories for our survival analysis: stage I to III (part of the con-
trol group, n5 108), stage IV (part of the control group, n5
38), and resection of MLN metastases (ie, metastasectomy;
our study cohort, n 5 9). Detailed information on patient
characteristics, tumor stage, and survival of these 3 groups
is provided in Table 3.
From the time of initial diagnosis of MLN metastases, our
study cohort had a significantly higher survival (log–rank
test, P , .0001) than did patients with stage IV disease
treated at our institution (Figure 3, A). Similarly, from the
time of resection of MLN metastases, our study cohort had
a significantly higher survival (log–rank test, P 5 .021)
than did patients with stage IV disease who were treated at
our institution (Figure 3, B).
For final analysis, we extracted 2 subsets to compare with
our study cohort.
Because no directly analogous group of patients with iso-
lated asynchronous MLN metastases who did not undergo
resection of metastases was available, we selected these 2 sub-
sets: (1) patients with lung parenchymal lesions who under-
went resection of metastases and (2) patients who had stage
IV disease with pulmonary metastases when they first came
to our institution and who did not undergo resection. From
the time of resection (for both our study cohort and the subset
with resectable lung parenchymal lesions), the survival was
higher (log–rank test; P5 .0025) than for the subset with un-
resectable pulmonary metastases (Figure 3, C). The survivalcic and Cardiovascular Surgery c Volume 135, Number 5 1025
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Stage I to III Stage IV
MLN metastasectomy
(study cohort) P*
No. of patients 108 38 9
Race .67
White (%) 81.5% 81.6% 88.9%
Black (%) 2.8% 10.5% 0%
Other (%) 15.7% 7.9% 11.1%
Sex .13
Male (%) 60.2% 76.3% 77.8%
Female (%) 39.8% 23.7% 22.2%
Age (y) 55.8 6 15.9 58.6 6 11.2 58.3 6 11.9 .47
Survival after initial treatment 0.001
1 year (%) 95% 55% 100%
2 years (%) 90% 37% 100%
3 years (%) 87% 30% 80%
4 years (%) 83% 20% 80%
5 years (%) 77% 20% 80%
Mean (y) 4.2 6 0.12 1.8 6 0.23 3.9 6 0.14
Median [range] (y) . 6.4 [0.02– .6.4] 1.04 [0.1–5.7] .23.5 [3.9–.23.5]
MLN, Mediastinal lymph node. *Analysis between groups.did not significantly differ between our study cohort and the
subset with lung parenchymal lesions. The median survival
time from the time of resection for the subset with lung paren-
chymal lesions that were resectable (Figure 3, C, ‘‘lung meta-
stasectomy) was 4 years (range, 2.07–. 6.5). For the subset
with lung parenchymal lesions that were not resectable (Fig-
ure 3, C, ‘‘stage IV–lung’’) the median survival from time
of initial treatment was 1.02 years (range, 0.1–5.6). Again,
for our study cohort, MLN metastasectomy, the median sur-
vival from time of resection was 3.2 years (range, 2.8–.
3.2). The Motzer score for the subset with lung parenchymal
lesions was 0.83 6 0.86, and for the subset of patients with
stage IV disease with pulmonary metastases, 0.81 6 0.75.
Discussion
Prognosis
Histologic analysis of RCC specimens provides insight into
the propensity for local–regional recurrence and metastases.
Papillary tumors have a tendency toward local–regional re-
currence with local lymph node invasion. However, tumors
with a clear cell variant have a tendency toward vascular
invasion; consequently, patients often present with distant
metastases.8,9 In our study cohort, the predominant cell
type was a clear cell variant.
In addition, the tumor grade provides prognostic informa-
tion. In 1982, Fuhrman, Lasky, and Limas8 established
a grading system (1 through 4) based on increasing nuclear
size, cellular irregularity, and nucleolar prominence, that cor-
relates with the survival. Other investigators have confirmed
the association between increasing grade and worsening sur-
vival.10-12 In particular, a larger tumor size (.8 cm) and1026 The Journal of Thoracic and Cardiovascular Surgery c Ma higher number of mitoses per 10 high-power fields (.1)
correspond to a worse survival.12 In our cohort of 9 patients,
all demonstrated angiolymphatic involvement, not entirely
unexpected given metastatic lymph node disease.
Motzer and associates developed a simple prognostic
scoring system for patients with RCC and asynchronous dis-
ease. Patients receive a score of 0 to 3 on the basis of the pres-
ence of each of the following risk factors (1 point for each risk
factor): low Karnofsky performance status (,80), anemia
(hemoglobin#13 g/dL for men and#11.5 g/dL for women),
and hypercalcemia (serum calcium .10 mg/dL). Patients
with no risk factors have a 25% 3-year survival. Patients
with 1 risk factor have an 11% 3-year survival, and those
with 2 or 3 risk factors, a 0% 3-year survival.3 In our study
cohort (Table 1), only 1 patient (male) had anemia (Motzer
score of 1). All other patients had a score of 0. On the basis
of this scoring system, our study cohort had a good progno-
sis. Of interest, lymph node involvement has been associated
with a worse survival.6,7,10,11
Most RCC recurrences or metastases occur within 5 years
after initial treatment; patients who are disease-free at 5 years
are traditionally considered to be cured. Although isolated
asynchronous metastases developed within 7 years after rad-
ical nephrectomy in most of our 9 study cohort patients, in 1
patient metastases developed 23 years after radical nephrec-
tomy. This patient had a low Furhman grade and a low Mot-
zer score, likely indicative of the indolent nature of that
particular tumor.
Resection of Metastases
Because resection of synchronous metastases does not im-
part a significant survival advantage,4 patients with stageay 2008
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Figure 3. A, Per the University of Minnesota Cancer Center Regis-
try, RCC and stage-specific overall survival time for theMLNmeta-
stasectomy cohort stage I, II, or III versus stage IV. B, Overall
survival for patients with stage IV disease from the time of diag-
nosis versus our study cohort from the time of resection of metas-
tases. C, Overall survival for patients with stage IV RCC with
pulmonary metastases on presentation from the time of theirThe Journal of ThorIV RCC are usually treated with either palliative or exper-
imental chemotherapy or with radiation therapy. Often,
patients with isolated asynchronous metastatic disease are
erroneously treated like patients with synchronous meta-
static disease. However, the 2 groups have different progno-
ses and different responses to treatment. Possibly because of
differences in tumor burden, patients who have RCC with
asynchronous RCC metastases have a more favorable prog-
nosis (median survival, 21 months)2 than patients with
synchronous metastases (median survival, 10 months).3
Furthermore, evidence is accumulating regarding the effi-
cacy of resection of metastases.
Cytoreduction through complete resection of locally re-
current RCC13 or asynchronous metastases5,7, 3-15 improves
the patient survivals. Resection of lung parenchymal metas-
tases is feasible6,7,16,17 and improves survival time (median,
35 months).4,6,7,16 Furthermore, unlike resection of locally
recurrent RCC, which often requires extensive intra-abdom-
inal resection,15 resection of pulmonary metastases is associ-
ated with minimal morbidity.4,6,7
Thus far, 1 previous case report has been published de-
scribing resection of RCC MLN.18 In that report, from Japan,
the patient survived at least 6 years after resection of metas-
tases. In our series of 9 patients, we have now demonstrated
that resection of metastases can be performed safely via tho-
racotomy or thoracoscopy with a brief hospital length of stay,
with minimal morbidity, with no postoperative mortality, and
with excellent long-term results. In skilled hands, a thoraco-
scopic approach is adequate. At both a median and mean fol-
low-up period of 3.2 years, of our 9 patients, 7 were alive and
well. These 7 patients had a significantly longer survival time
(mean, 47 months) than other patients with stage IV disease
treated at our institution.
Chemoradiation, Tumor Vaccines, and Cytokine
Therapy
In general, all patients with RCC are treated with a nephrec-
tomy. For stage I and II, this could be a simple nephrectomy
or a radical nephrectomy (the standard for stages III and IV).
Limited clinical data are available for the use of standardized
chemotherapeutic regimens for patients with advanced
RCC.19 However, the use of IL-2 and interferon-alpha was
associated in one study with a response rate of around
15%.20 In other studies, a tendency to relapse was noted in
patients treated with IL-2 alone, whereas relapse was less
likely in patients who underwent cytoreduction via resection
diagnosis to the survival from the time of metastasectomy for
the MLN metastasectomy and lung parenchymal metastasectomy
cohorts. Above the abscissa, censored Kaplan–Meier survival
curve, with log–rank analysis and the number of patients at risk.
RCC, Renal cell carcinoma; MLN, mediastinal lymph node.acic and Cardiovascular Surgery c Volume 135, Number 5 1027
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apy with a complete response.14,21
Recently, novel chemotherapeutic agents have been added
to the standard regimen for patients with metastatic RCC:
sorafenib in December 2005 and sunitinib in January 2006.
Two additional agents, far along in clinical phase trials,
show potential: bevacizumab, an antibody against vascular
endothelial growth factor, and temsirolimus, a mammalian
target of rapamycin inhibitor.
The large multivalent immunogen vaccine, an autologous
vaccine strategy developed at the University of Minnesota,
continues to be experimental. Additionally, 852A, an m-toll
agonist, and cetuximab, an antibody against epidermal
growth factor receptor, are both experimental agents that cur-
rently are used at our institution as part of another protocol.
At the time of RCC recurrence, cytokine therapy with high-
dose IL-2 can be used (if not used before); sunitinib or sora-
fenib can be employed.
Sunitinib, a small molecule receptor tyrosine kinase inhib-
itor, has a possible mechanism of action through the vascular
endothelial growth factor receptor. Sorafenib, a small mole-
cule inhibitor of the Raf kinase, potentially works through
the vascular endothelial growth factor receptor as well as
platelet-derived growth factor. Both chemotherapeutic agents
target vascular invasion.
Conclusion
Most patients with RCC who have a 5-year disease-free inter-
val are considered cured, but our series of 9 patients demon-
strated that MLN metastases can occur more than 20 years
after initial treatment. Consequently, long-term surveillance
may be required to appropriately monitor patients with
RCC. Resection of isolated asynchronous MLN metastases
is safe and may offer a survival advantage; such patients
should be offered careful surgical evaluation for resection
of metastases.
We acknowledge Mary Knatterud, PhD, for her editorial assis-
tance with this manuscript.
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